Table 1.
SARS-CoV‑2 vaccines
| Vaccine | Company | Remarks |
|---|---|---|
| BNT162b2 | BioNTec/Pfizer, Germany & US | Nucleoside-modified mRNA encoding viral spike glycoprotein of SARS-CoV‑2 |
| mRNA-1273 | Moderna; US | Nucleoside-modified mRNA encoding viral spike glycoprotein of SARS-CoV‑2 |
| AZD1222 | AstraZeneca, Sweden & UK | Recombinant, replication-deficient chimpanzee adenovirus vector encoding SARS-CoV‑2 spike glycoprotein |
| Ad26.CoV‑2.S | Janssen-Cilag/Johnson & Johnson, US & Belgium | Human adenovirus serotype 26 carrying the spike glycoprotein of SARS-CoV‑2 |
| Gam-COVID-Vac | Gamaleya, Russia (Sputnik V) | Human adenovirus serotype 26 (first shot) and serotype 5 (second shot) carrying the spike glycoprotein of SARS-CoV‑2 |
| Ad5-nCoV | CanSino, China | Recombinant adenovirus serotype 5 carrying the spike glycoprotein of SARS-CoV‑2 |
| NVX-CoV2373 | Novavax, US | Full-length spike protein nanoparticle plus matrix M1, saponin-based adjuvant |
| BBV-152 | Bharat, India | Based on whole inactivated SARS-CoV‑2 |
| CoronaVAC | SinoVac, China | Based on whole inactivated SARS-CoV‑2 |
| Co-VLP | Medicago, Canada & Italy | Spike proteins aggregated as virus-like particles, tobacco plant-based adjuvant |
| ZF2001 | Zhifei Longcom | Recombinant tandem-repeat dimeric receptor binding domain-based protein subunit vaccine |
| INO-4800 | Inovio, US | DNA vaccine delivered intradermally with CELLECTRA® electroporation (EP) delivery system |